Non-animal derived culture medium for filling test medium 'Trypticase Soy Broth γ-ray'
We deliver non-animal-derived culture media for filling tests from a factory dedicated to animal-free products! Used to ensure sterility in the manufacturing lines of sterile pharmaceuticals and beverages.
The "BD BBL Select APS Triptych Case Soybroth" series is a soybean-casein-digest medium that complies with the three-pronged pharmacopoeia for medium filling tests. To provide safer products, it is manufactured in a dedicated animal-free facility that does not use animal-derived materials or antibiotics. Additionally, it incorporates an even stricter quality system than conventional factories to minimize the possibility of cross-contamination. 【Features】 ■ Soybean-casein-digest medium that has been γ-irradiated for medium filling tests and complies with the three-pronged pharmacopoeia ■ Animal-free, reducing BSE/TSE risks ■ Manufactured in a dedicated animal-free facility ■ Mycoplasma/endotoxin testing conducted
Inquire About This Product
basic information
【Product Information】 ■Non-animal derived product ・Product Name: BD BBL Select APS Triptych Case Soybroth γ-ray irradiated ・Packaging Unit: 10Kg package 【Composition】 (per 1L of purified water) ■Soy Peptone .......................... 17.0g ■Yeast Extract .......................... 2.0g ■Sodium Chloride ....................... 5.0g ■Dipotassium Hydrogen Phosphate ... 2.5g ■Glucose .................................. 2.5g ■pH 7.3±0.2 *The composition values are reference amounts per liter. *For more details, please contact us.
Price range
P3
Delivery Time
Applications/Examples of results
【Purpose】 It is used for testing to verify the sterility assurance of manufacturing lines for sterile pharmaceuticals and beverages (such as bottled products).
Line up（1）
| Model number | overview |
|---|---|
| 214886 | BD BBL Select APS Triptych Case Soy Bros γ-ray irradiated (10kg) |
catalog（1）
Download All Catalogs
Company information
BD Japan is the Japanese subsidiary of BD, one of the world's leading medical device and medtech companies headquartered in New Jersey, USA. BD aims to lead the world in medical technology, seeking new insights in the healthcare field and improving the quality of diagnosis and treatment, with the purpose of realizing "The future of healthcare for all(TM)." By developing innovative technologies and services related to patient treatment and healthcare processes, BD supports those working on the front lines of healthcare. With approximately 77,000 employees worldwide, BD staff support researchers in the development of next-generation diagnostic and therapeutic methods and strive daily to enhance the safety of healthcare professionals and the efficiency of medical practices in clinical settings. By partnering with healthcare institutions in countries around the world and addressing global priority issues, BD contributes to improving healthcare outcomes, reducing costs, increasing efficiency, enhancing safety, and promoting access to healthcare through close collaboration with its customers, the healthcare institutions.
